Forecast

There is no analyst data available for this company.

News Go to news feed

Abivax expects Q2 EPS of -0.839 EUR and revenue of about 0.7 million EUR

Abivax is expected to publish its quarterly figures for 30/06/2026 on 21/09/2026. Analysts on average forecast earnings of -0.839 EUR per share for the quarter (previous year: -0.760 EUR) and revenue of around 0.7 million EUR (previous year: 0.0 million EUR). For the current fiscal year, the average analyst outlook is a loss of -3.309 EUR per share and revenue of about 3.8 million EUR. » More on finanzen.net
Abivax expects quarterly results on September 21, 2026 with another EPS loss

For the quarter for which Abivax will report figures on September 21, 2026, five analysts forecast an average earnings per share of -0.959 USD, a decline of 11.51% from -0.860 USD a year earlier. Six analysts expect revenue of on average 0.8 million USD versus 0.0 million in the year‑ago quarter. For the fiscal year, 13 analysts on average forecast a loss per share of -3.778 USD (prior year -5.450 USD) and 14 analysts see revenue at an average of 4.4 million USD. » More on finanzen.net
Abivax back in focus among hedge funds after rally — obefazimod brings opportunities and risks

Abivax was a share-price driver in 2025 but is currently trading with high volatility and about 15 percent below the start of the year. The business model is concentrated on obefazimod for chronic inflammatory bowel diseases; a US approval application is planned for this year. Safety concerns over reported cancer cases were mitigated by additional data, after which analysts raised price targets and see, on average, upside potential of just over 60 percent; 7 of 8 analysts recommend the stock as a buy. Thanks to a capital increase, financing is secured until 2029, although losses are expected at least through 2027. » More on handelsblatt.com

Financials

In the last quarter, Abivax had revenue of -€2.02M and net profit of -€235.32M

(EUR)	December 2025	YoY
Revenue	-2.02M	-
Gross profit	-3.09M	-
Net profit	-235.32M	-
EBITDA	-155.96M	-

Fundamentals

Metric	Value
Market capitalization	€7.76B
Number of shares	79.3M
52-week high/low	€99.60 - €5.68
Dividends	No
Beta	-0.21
P/E ratio	-20.28
PEG ratio	0.33
P/B ratio	14.96
P/S ratio	0.00

Company profile

ABIVAX Société Anonyme erforscht und optimiert Medikamente zur Behandlung von Entzündungskrankheiten, Infektionskrankheiten und Krebs in Frankreich. Zu den wichtigsten Produkten des Unternehmens gehören ABX464, das sich in klinischen Studien der Phase IIb zur Behandlung von Colitis ulcerosa und Morbus Crohn sowie von COVID-19 befindet, eine klinische Studie der Phase IIa zur Behandlung von rheumatoider Arthritis und eine klinische Studie der Phase IIa zur Behandlung von HIV-Patienten, die eine Virusremission anstreben. Außerdem entwickelt es ABX 196, einen Kandidaten zur Stärkung des Immunsystems, der sich in klinischen Phase-1/2-Studien zur Behandlung von Leberzellkrebs befindet. Darüber hinaus beteiligt sich das Unternehmen an Forschungsprogrammen zur Behandlung von Dengue-Fieber, Grippe und Respiratorischem Synzytialvirus. ABIVAX Société Anonyme hat Lizenzverträge mit dem französischen Nationalen Zentrum für wissenschaftliche Forschung, der Universität Montpellier und dem Institut Curie abgeschlossen. Das Unternehmen wurde im Jahr 2013 gegründet und hat seinen Hauptsitz in Paris, Frankreich.